Fusion Capital LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 92.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,799 shares of the company’s stock after selling 21,764 shares during the quarter. Fusion Capital LLC’s holdings in Eli Lilly and Company were worth $844,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Silicon Valley Capital Partners purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $25,000. Bogart Wealth LLC increased its stake in Eli Lilly and Company by 193.3% during the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. Activest Wealth Management purchased a new position in shares of Eli Lilly and Company in the second quarter worth $40,000. Laffer Tengler Investments acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $33,000. Finally, Raleigh Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 156.4% during the first quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock valued at $34,000 after buying an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 81.38% of the company’s stock.
Insiders Place Their Bets
In related news, major shareholder Lilly Endowment Inc sold 3,000 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $528.13, for a total transaction of $1,584,390.00. Following the completion of the sale, the insider now directly owns 100,696,849 shares in the company, valued at $53,181,026,862.37. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 3,000 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $528.13, for a total value of $1,584,390.00. Following the completion of the transaction, the insider now directly owns 100,696,849 shares in the company, valued at $53,181,026,862.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares in the company, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 907,655 shares of company stock valued at $21,078,714,805. Insiders own 0.13% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages recently commented on LLY. Bank of America upped their target price on Eli Lilly and Company from $600.00 to $700.00 in a research report on Friday, October 6th. Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $640.00 to $673.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 11th. Citigroup boosted their target price on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the company a “buy” rating in a research report on Monday. 22nd Century Group reiterated a “maintains” rating on shares of Eli Lilly and Company in a research note on Tuesday, June 27th. Finally, Royal Bank of Canada boosted their price objective on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $555.83.
Check Out Our Latest Research Report on LLY
Eli Lilly and Company Price Performance
Shares of NYSE:LLY traded up $1.40 during midday trading on Monday, hitting $586.04. The company’s stock had a trading volume of 1,129,820 shares, compared to its average volume of 3,032,473. The company has a market cap of $556.32 billion, a P/E ratio of 81.51, a price-to-earnings-growth ratio of 3.45 and a beta of 0.33. Eli Lilly and Company has a 12-month low of $309.20 and a 12-month high of $629.97. The business’s 50 day simple moving average is $565.42 and its 200 day simple moving average is $481.27. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The company had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.25 EPS. On average, analysts forecast that Eli Lilly and Company will post 6.65 EPS for the current year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.